Pd19-11 diabetes causes temporal changes in cholinergic-mediated bladder contractility due to inflammation via the nlrp3 inflammasome in female akita mice

You have accessJournal of UrologyCME1 Apr 2023PD19-11 DIABETES CAUSES TEMPORAL CHANGES IN CHOLINERGIC-MEDIATED BLADDER CONTRACTILITY DUE TO INFLAMMATION VIA THE NLRP3 INFLAMMASOME IN FEMALE AKITA MICE Michael Odom, Francis Hughes, Huixia Jin, and J. Todd Purves Michael OdomMichael Odom More articles by this author , Francis HughesFrancis Hughes More articles by this author , Huixia JinHuixia Jin More articles by this author , and J. Todd PurvesJ. Todd Purves More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003285.11AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The most common complication of diabetes is bladder dysfunction which is driven in the female Akita type 1 diabetic mouse by inflammation mediated by the NLRP3 inflammasome. It is unclear how diabetes affects signaling pathways responsible for bladder contractility and if this is mediated by NLRP3. Using a female Akita model that develops a temporal progression from bladder overactivity to underactivity, we investigated effects on the cholinergic signaling pathways. To accomplish this we utilized ex vivo myography to determine how neurotransmitter release from efferent nerve terminals and muscarinic receptor activation is impacted in bladders of non-diabetic and diabetic mice±the NLRP3 gene. METHODS: Akita mice were crossbred with NLRP3-/- mice to yield non-diabetics and diabetics±NLRP3 gene. Females were aged to 15 and 30 weeks when respective overactive and underactive bladder phenotypes are evident. For ex vivo myography, bladder strips with intact mucosa were used. Efferent neurotransmitter-mediated contractions were assessed using electric field stimulation (EFS)±the muscarinic receptor antagonist atropine. Contractility to carbachol, a muscarinic receptor agonist, was also assessed (n=5-10 per group). RESULTS: At 15 weeks, diabetic NLRP3+/+ mice have increased EFS contractility (p<0.05) but NLRP3 gene deletion prevented this pathology in diabetics. At 30 weeks, EFS contractions were no longer dysregulated. EFS was repeated in the presence of atropine to determine the cholinergic contribution. In the presence of atropine, no significant differences were noted in diabetic animals – indicating the increase in contractility at 15 weeks was due to upregulated cholinergic mechanisms. No changes in contractions to carbachol were noted at either time point. This indicates the increased contractility to EFS was not due to increased muscarinic receptor activity but rather an increase in acetylcholine release. CONCLUSIONS: Diabetes increases cholinergic neurotransmitter release and bladder contractility in mice with an overactive bladder as a consequence of inflammation driven by NLRP3. This suggests an NLRP3 inhibitor may be an effective therapy to prevent overactive bladder and eliminate the need for conventional anti-cholinergic treatments. Source of Funding: NIH-K12 DK100024; NIH-RO1 DK117890 © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e581 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Michael Odom More articles by this author Francis Hughes More articles by this author Huixia Jin More articles by this author J. Todd Purves More articles by this author Expand All Advertisement PDF downloadLoading ...